Article summary
The Medicines and Healthcare products Regulatory Agency’s (MHRA) Chief Executive, Dr June Raine, has published a statement on the coronavirus (COVID-19) booster vaccine programme for winter 2021–2022. The statement calls the booster programme an ‘important regulatory change’ for providing more options for the vaccination programme. The regulatory decision was made after a review by the MHRA and the Commission on Human Medicines on the waning effectiveness of the vaccine after the second dose. Booster vaccines can be delivered at the same time as flu vaccines and the approved vaccines are Pfizer, Astrazeneca and Moderna.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial